<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590482</url>
  </required_header>
  <id_info>
    <org_study_id>Letrozole /pretreatment</org_study_id>
    <nct_id>NCT04590482</nct_id>
  </id_info>
  <brief_title>Letrozole Pretreatment With Misoprostol Induction of Abortion in First Trimester Missed Abortion</brief_title>
  <official_title>Use of Letrozole Pretreatment With Misoprostol for Induction of Abortion in First Trimester Missed Abortion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shereen Rady Abou El-fetouh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      this study will compare the efficacy of using letrozole pre treatment before misoprostol&#xD;
      versus using misoprostol only in the induction of first trimester missed abortion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention type: drug&#xD;
&#xD;
      Intervention name: letrozole then misoprostol&#xD;
&#xD;
      Description :letrozole 2.5mg twice per day for 2days then misoprostol 800mcg for all patients&#xD;
      to induce abortion&#xD;
&#xD;
      Arm group label:study group&#xD;
&#xD;
      Intervention type :drug&#xD;
&#xD;
      Intervention name:placebo then misoprostol&#xD;
&#xD;
      Description : placebo for 2days then 800mcg misoprostol to all patients to induce abortion&#xD;
&#xD;
      Arm group label: control group&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2020</start_date>
  <completion_date type="Anticipated">May 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 16, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>participant- care provider -investigator- outcomes assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Complete abortion</measure>
    <time_frame>6 hours</time_frame>
    <description>incidence of complete abortion without the need of surgical evacuation among 110patients in which 55 of patients took letrozole before misoprostol and the other 55 patients took placebo before misoprostol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>surgical evacuation</measure>
    <time_frame>6 hours</time_frame>
    <description>surgical evacuation for the remnants of conception among 110 patients in which 55 took letrozole before misoprostol and other 55 patients who took placebo before misoprostol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Missed Abortion</condition>
  <arm_group>
    <arm_group_label>letrozole then misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>description:letrozole 2.5 mg each 12hours for 2 days at home followed by misoprostol 800mcg vaginally at hospital repeated after 4 hours if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo then misoprostol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Description:placebo each 12 hours for 2days at home followed by 800mcg misoprostol vaginally at hospital and repeat dose after 4 hours if needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion</description>
    <arm_group_label>letrozole then misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion</description>
    <arm_group_label>placebo then misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Maternal age more than 18 years old.&#xD;
&#xD;
          2. Gestational age less than 13 weeks confirmed by ultrasound scan on day 1 of the study.&#xD;
&#xD;
          3. Hemoglobin &gt;10 g/dl&#xD;
&#xD;
          4. Missed abortion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mullerian Uterine anomalies as septate, bicornuate uterus.&#xD;
&#xD;
          2. Fibroid uterus.&#xD;
&#xD;
          3. Coagulopathy.&#xD;
&#xD;
          4. Medical disorder that contraindicate induction of abortion.&#xD;
&#xD;
          5. Allergy to misoprostol or letrozole.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Ages of eligibility :18years and older&#xD;
sex eligibility :female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shereen khedr</last_name>
    <role>Principal Investigator</role>
    <affiliation>AinShams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>shereen khedr</last_name>
    <phone>01011304478</phone>
    <email>a.m.agdy@hotmail.com</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Shereen Rady Abou El-fetouh</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Missed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

